These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 35272955

  • 1. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Cortot A, Le X, Smit E, Viteri S, Kato T, Sakai H, Park K, Camidge DR, Berghoff K, Vlassak S, Paik PK.
    Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
    [Abstract] [Full Text] [Related]

  • 2. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.
    Reale ML, Passiglia F, Cappuzzo F, Minuti G, Occhipinti M, Bulotta A, Delmonte A, Sini C, Galetta D, Roca E, Pelizzari G, Cortinovis D, Gariazzo E, Pilotto S, Citarella F, Bria E, Muscolino P, Pozzessere D, Carta A, Pignataro D, Calvetti L, Leone F, Banini M, Di Micco C, Baldini E, Favaretto A, Malapelle U, Novello S, Pasello G, Tiseo M.
    ESMO Open; 2024 Sep; 9(9):103680. PubMed ID: 39214048
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM, Dawar R, Rodriguez E, Ikpeazu CV.
    J Hematol Oncol; 2021 Aug 23; 14(1):129. PubMed ID: 34425853
    [Abstract] [Full Text] [Related]

  • 4. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
    Mazieres J, Vioix H, Pfeiffer BM, Campden RI, Chen Z, Heeg B, Cortot AB.
    Clin Lung Cancer; 2023 Sep 23; 24(6):483-497. PubMed ID: 37451931
    [Abstract] [Full Text] [Related]

  • 5. Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.
    Miao K, Zhang X, Wang H, Si X, Zhang L.
    Thorac Cancer; 2023 May 23; 14(13):1162-1170. PubMed ID: 36944506
    [Abstract] [Full Text] [Related]

  • 6. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL, Smit EF, Bauer TM.
    Cancer Treat Rev; 2021 Apr 23; 95():102173. PubMed ID: 33740553
    [Abstract] [Full Text] [Related]

  • 7. The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation.
    Deng HY, Qiu XM, Zhu DX, Tang XJ, Zhou Q.
    J Cancer Res Clin Oncol; 2023 Jul 23; 149(8):4623-4628. PubMed ID: 36171456
    [Abstract] [Full Text] [Related]

  • 8. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
    Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T.
    J Hematol Oncol; 2022 Jun 11; 15(1):79. PubMed ID: 35690785
    [Abstract] [Full Text] [Related]

  • 9. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM.
    J Thorac Oncol; 2017 Jan 11; 12(1):137-140. PubMed ID: 27666659
    [Abstract] [Full Text] [Related]

  • 10. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
    Wolf J, Hochmair M, Han JY, Reguart N, Souquet PJ, Smit EF, Orlov SV, Vansteenkiste J, Nishio M, de Jonge M, Akerley W, Garon EB, Groen HJM, Tan DSW, Seto T, Frampton GM, Robeva A, Carbini M, Le Mouhaer S, Yovine A, Boran A, Bossen C, Yang Y, Ji L, Fairchild L, Heist RS.
    Lancet Oncol; 2024 Oct 11; 25(10):1357-1370. PubMed ID: 39362249
    [Abstract] [Full Text] [Related]

  • 11. The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation.
    Rocco D, Gravara LD, Palazzolo G, Gridelli C.
    Curr Med Chem; 2024 Oct 11; 31(21):3043-3056. PubMed ID: 37534484
    [Abstract] [Full Text] [Related]

  • 12. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
    Morise M, Kato T, Matsumoto S, Inoue T, Sakamoto T, Tokito T, Atagi S, Kozuki T, Takeoka H, Chikamori K, Shinagawa N, Tanaka H, Horii E, Adrian S, Bruns R, Johne A, Paik PK, Sakai H.
    Cancer Sci; 2024 Apr 11; 115(4):1296-1305. PubMed ID: 38402853
    [Abstract] [Full Text] [Related]

  • 13. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
    Kanemura H, Takeda M, Shimizu S, Nakagawa K.
    Thorac Cancer; 2021 Feb 11; 12(4):549-552. PubMed ID: 33347701
    [Abstract] [Full Text] [Related]

  • 14. Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
    Veillon R, Sakai H, Le X, Felip E, Cortot AB, Smit EF, Park K, Griesinger F, Britschgi C, Wu YL, Melosky B, Baijal S, Jr GC, Sedova M, Berghoff K, Otto G, Paik PK.
    Clin Lung Cancer; 2022 Jun 11; 23(4):320-332. PubMed ID: 35466070
    [Abstract] [Full Text] [Related]

  • 15. Going After METex14 in NSCLC.
    Cancer Discov; 2019 Aug 11; 9(8):OF9. PubMed ID: 31209157
    [Abstract] [Full Text] [Related]

  • 16. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
    Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.
    Clin Cancer Res; 2020 Jan 15; 26(2):439-449. PubMed ID: 31548343
    [Abstract] [Full Text] [Related]

  • 17. Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
    Xia Y, Jin R, Li M, Lan F, Zhu H, Yu Y, Miao D, Wang Q, Zhou Y, Selvaggi G, Ying S, Zhang J, Shen H, Le X, Li W.
    Cancer Lett; 2023 May 01; 561():216140. PubMed ID: 36948240
    [Abstract] [Full Text] [Related]

  • 18. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T, Liang Y, Zhu V, Ou SI.
    Lung Cancer; 2017 Jan 01; 103():27-37. PubMed ID: 28024693
    [Abstract] [Full Text] [Related]

  • 19. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
    Sakai H, Morise M, Kato T, Matsumoto S, Sakamoto T, Kumagai T, Tokito T, Atagi S, Kozuki T, Tanaka H, Chikamori K, Shinagawa N, Takeoka H, Bruns R, Straub J, Schumacher KM, Paik PK.
    Jpn J Clin Oncol; 2021 Aug 01; 51(8):1261-1268. PubMed ID: 34037224
    [Abstract] [Full Text] [Related]

  • 20. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
    Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X.
    N Engl J Med; 2020 Sep 03; 383(10):931-943. PubMed ID: 32469185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.